Drugmaker | featured news

FDA Did the Right Thing in Pulling Avastin for Breast Cancer

FDA Did the Right Thing in Pulling Avastin for Breast Cancer

If you want the FDA to approve more innovative, new drugs based on promising but early clinical results, you have to give the FDA a way to revoke those approvals later on, should larger trials prove that those drugs aren't as safe or effective as they first seemed. This is why the FDA should be congratulated for the way it has handled the Avastin breast cancer saga, and why I hope we will see the FDA handle more cases like this one, not less.

 

Obama executive order targets drug shortages

President Obama Monday is pushing drug makers and federal regulators to do more to address dangerous shortages of critical medicines, sidestepping a deadlocked Congress that has not moved legislation to help patients suffering from deadly illnesses.

 

Pfizer Is Said to Pursue Nonprescription Lipitor

Pfizer hopes to have an over-the-counter version of the world’s best-selling drug after it loses patent protection.

 

FDA to hear appeal on breast cancer drug Avastin

The best-selling cancer drug in the world comes under federal scrutiny as drugmaker Roche makes a last-ditch effort to keep Avastin approved ...

 

Shanghai Pharma Seeks up to US$2.22 Bln in HK IPO

Shanghai Pharmaceuticals is seeking to raise up to US$2.22 billion in an initial public offering on the Hong Kong stock exchange on May 20.

 

F.D.A. Pulls Painkiller Due to Risks

The maker of the painkiller Darvon is pulling the drug off the market at the request of public health officials who say the 50-year-old pill causes potentially deadly heart rhythms.

 

Pfizer 3Q profit down 70 percent due to charges

Pharmaceutical giant Pfizer Inc. says revenue in the third quarter jumped 39 percent due to its acquisition of fellow drugmaker Wyeth, but hefty charges dragged its profit down 70 percent.

 

Pfizer to buy King Pharma for $3.6 billion in cash

Pfizer to buy King Pharma for $3.6 billion in cash

Pfizer Inc, the world's biggest drugmaker, has agreed to buy King Pharmaceuticals Inc for $3.6 billion, expanding its presence in the market for pain drugs.

 

Sanofi launches hostile $18.5 billion bid for Genzyme

French drugmaker Sanofi-Aventis launched a hostile bid for Genzyme at $69 per share on Monday, taking its $18.5 billion offer direct to shareholders after Genzyme management refused to negotiate.

<

 

Company Recalls Infant Formula on Bug Contaminant

Drugmaker Abbott Laboratories says it is recalling a line of infant formula which may be contaminated with insect parts.

Senh: How the hell do bugs get into infant formula?

 

Subscribe to this RSS topic: Syndicate content